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reamble
primary challenge in the development of clinical practice
uidelines is keeping pace with the stream of new data on
hich recommendations are based. In an effort to respond
ore quickly to new evidence, the American College ofardiology Foundation/American Heart Association
ACCF/AHA) Task Force on Practice Guidelines has
reated a “focused update” process to revise the existing
uideline recommendations that are affected by the evolving
ata or opinion. Prior to the initiation of this focused
pproach, periodic updates and revisions of existing guide-
ines required up to 3 years to complete. Now, however, new
vidence will be reviewed in an ongoing fashion to respond
ore efficiently to important science and treatment trends
hat could have a major impact on patient outcomes and
uality of care. Evidence will be reviewed at least twice a
ear, and updates will be initiated on an as-needed basis as
uickly as possible, while maintaining the rigorous meth-
dology that the ACCF and AHA have developed during
heir 25 years of partnership.
These updated guideline recommendations reflect a
onsensus of expert opinion after a thorough review
rimarily of late-breaking clinical trials identified
hrough a broad-based vetting process as being important
o the relevant patient population, as well as of other new
ata deemed to have an impact on patient care (see
ection 1.1., Methodology and Evidence Review, for
etails regarding this focused update). This focused
pdate is not intended to represent an update based on a
ull literature review from the date of the previous
uideline publication. Specific criteria/considerations for
nclusion of new data include the following:
• publication in a peer-reviewed journal;
• large, randomized, placebo-controlled trial(s);
• nonrandomized data deemed important on the basis of
results impacting current safety and efficacy assumptions;
• strength/weakness of research methodology and findings;
• likelihood of additional studies influencing current
findings;
• impact on current performance measure(s) and/or likeli-
hood of need to develop new performance measure(s);
• requests and requirements for review and update fromthe practice community, key stakeholders, and other
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potential bias;
• number of previous trials showing consistent results; and
• need for consistency with a new guideline or guideline
revision.
In analyzing the data and developing updated recommen-
ations and supporting text, the focused update writing
roup used evidence-based methodologies developed by the
CCF/AHA Task Force on Practice Guidelines, which are
escribed elsewhere (1).
The schema for class of recommendation and level of
vidence is summarized in Table 1, which also illustrates
ow the grading system provides an estimate of the size of
he treatment effect and an estimate of the certainty of the
reatment effect. Note that a recommendation with Level of
vidence B or C does not imply that the recommendation
s weak. Many important clinical questions addressed in
uidelines do not lend themselves to clinical trials. Although
andomized trials may not be available, there may be a very
able 1. Applying Classification of Recommendations and Leve
Data available from clinical trials or registries about the usefulness/efficacy in different subpo
ailure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply th
end themselves to clinical trials. Even though randomized trials are not available, there may b
CCF/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use wh
xpress a complete thought, such that a recommendation, even if separated and presented apar
he full intent of the recommendation. It is hoped that this will increase readers’ comprehensiolear clinical consensus that a particular test or therapy is aseful and effective. Both the class of recommendation and
evel of evidence listed in the focused updates are based on
onsideration of the evidence reviewed in previous iterations
f the guideline and in the focused update. Of note, the
mplications of older studies that have informed recommen-
ations but have not been repeated in contemporary settings
re considered carefully.
The ACCF/AHA practice guidelines address patient
opulations (and healthcare providers) residing in North
merica. As such, drugs that are not currently available in
orth America are discussed in the text without a specific
lass of recommendation. For studies performed in large
umbers of subjects outside of North America, each writing
ommittee reviews the potential impact of different practice
atterns and patient populations on the treatment effect and
n the relevance to the ACCF/AHA target population to
etermine whether the findings should inform a specific
ecommendation.
The ACCF/AHA practice guidelines are intended to
vidence
s, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart
ecommendation is weak. Many important clinical questions addressed in the guidelines do not
y clear clinical consensus that a particular test or therapy is useful or effective. †In 2003, the
ing recommendations. All guideline recommendations have been written in full sentences that
he rest of the document (including headings above sets of recommendations), would still convey
guidelines and will allow queries at the individual recommendation level.l of E
pulation
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en writssist healthcare providers in clinical decision making by
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November 24, 2009:2102–28 Focused Update on Perioperative Beta Blockadeescribing a range of generally acceptable approaches for the
iagnosis, management, and prevention of specific diseases
r conditions. The guidelines attempt to define practices
hat meet the needs of most patients in most circumstances.
he ultimate judgment regarding care of a particular patient
ust be made by the healthcare provider and patient in light
f all the circumstances presented by that patient. Thus,
here are circumstances in which deviations from these
uidelines may be appropriate. Clinical decision making
hould consider the quality and availability of expertise in
he area where care is provided. These guidelines may be
sed as the basis for regulatory or payer decisions, but the
ltimate goal is quality of care and serving the patient’s best
nterests.
Prescribed courses of treatment in accordance with these
ecommendations are only effective if they are followed by
he patient. Because lack of patient adherence may adversely
ffect treatment outcomes, healthcare providers should
ake every effort to engage the patient in active participa-
ion with prescribed treatment.
The ACCF/AHA Task Force on Practice Guidelines
akes every effort to avoid actual, potential, or perceived
onflicts of interest that may arise as a result of industry
elationships or personal interests among the writing
ommittee. Specifically, all members of the writing com-
ittee, as well as peer reviewers of the document, are
sked to disclose all such relationships pertaining to the
rials and other evidence under consideration (see Ap-
endixes 1 and 2). Final recommendations were balloted
o all writing committee members. Writing committee
embers with relevant relationships with industry were
equired to recuse themselves from voting on that rec-
mmendation. Previous writing committee members who
id not participate are not listed as authors of this focused
pdate.
With the exception of the recommendations presented
ere, the full-text guideline remains current. Only the
ecommendations from the affected section(s) of the full-
ext guideline are included in this focused update. For easy
eference, all recommendations from any section of a
uideline impacted by a change are presented with notation
s to whether they remain current, are new, or have been
odified. When evidence impacts recommendations in
ore than 1 set of guidelines, those guidelines are updated
oncurrently.
The recommendations in this focused update will be
onsidered current until they are superseded by another
ocused update or the full-text guidelines are revised. This
ocused update is published in the November 24, 2009,
ssues of the Journal of the American College of Cardiology and
irculation as an update to the full-text guideline, and a
evised version of the 2007 full-text guideline that incorpo-
ates the focused update has also been e-published in these
ssues and is available on the respective Web sites “2). For easy reference, this online-only version denotes
ections that have been updated.
Alice K. Jacobs, MD, FACC, FAHA,
Chair, ACCF/AHA Task Force on Practice Guidelines
Sidney C. Smith, Jr, MD, FACC, FAHA,
Immediate Past Chair, ACCF/AHA
Task Force on Practice Guidelines
. Introduction
.1. Methodology and Evidence Review
ate-breaking clinical trials presented at the 2008 annual
cientific meetings of the ACCF, AHA, and European
ociety of Cardiology, as well as selected other data through
une 2009, were reviewed by the standing guideline writing
ommittee along with the parent task force and other
xperts to identify those trials and other key data that may
mpact guideline recommendations. On the basis of the
riteria/considerations noted previously, recent trial data
nd other clinical information were considered important
nough to prompt a focused update of the “ACC/AHA
007 Guidelines on Perioperative Cardiovascular Evalua-
ion and Care for Noncardiac Surgery” (3). This update
ddresses predominantly the prophylactic use of beta block-
rs perioperatively to minimize cardiac risk, but it does not
over other legitimate uses of beta blockers (e.g., as an adjunct
n anesthetic regimens, for intraoperative control of heart rate
r blood pressure, or to achieve heart rate control in common
erioperative arrhythmias such as atrial fibrillation).
When considering the new data for this focused update,
he writing group faced the task of weighing evidence from
tudies enrolling large numbers of subjects outside North
merica. While noting that practice patterns and the rigor
pplied to data collection, as well as the genetic make-up of
ubjects, may influence the observed magnitude of a treat-
ent’s effect, the writing group believed the data were
elevant to formulation of recommendations for periopera-
ive management in North America. The reasons for this
ecision include the following: 1) The use of detailed
rotocol-driven management strategies likely reduced treat-
ent variability among sites; and 2) it may be impractical to
xpect that the thousands of patients undergoing noncardiac
urgery who are needed to meet the estimated sample size
or contemporary clinical trials would be enrolled exclusively
t North American sites.
To provide clinicians with a comprehensive set of data,
henever possible, the exact event rates in various treatment
rms of clinical trials are presented to permit calculation of
he absolute risk difference and number needed to treat
NNT) or harm. The relative treatment effects are described
ither as odds ratio (OR), relative risk (RR), or hazard ratio
HR), depending on the format in the original publication.
Consult the full-text version or executive summary of the
ACC/AHA 2007 Guidelines on Perioperative Cardiovas-
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olicy on clinical areas not covered by the focused update.
ndividual recommendations updated in this focused update
ill be incorporated into future revisions and/or updates of
he full-text guidelines.
.2. Organization of Committee and
elationships With Industry and Other Entities
or this focused update, all members of the 2007 Perioperative
uideline Writing Committee were invited to participate;
hose who agreed (referred to as the 2009 Focused Update
riting Group) were required to disclose all relationships with
ndustry and other entities relevant to the data under consid-
ration. Each recommendation required a confidential vote by
he writing group members before and after external review of
he document. Any writing group member with a relationship
ith industry relevant to the recommendation was recused
rom voting on that recommendation. The committee in-
luded representatives from the American Society of Echocar-
iography (ASE), Heart Rhythm Society (HRS), Society of
ardiovascular Anesthesiologists (SCA), Society for Cardiac
ngiography and Interventions (SCAI), Society for Vascular
edicine (SVM), and Society for Vascular Surgery (SVS).
.3. Document Review and Approval
his document was reviewed by 2 official reviewers nomi-
ated by the ACCF and 2 official reviewers nominated by
he AHA, as well as 2 reviewers each from the ASE,
merican Society of Nuclear Cardiology, HRS, SCA,
CAI, SVM, and the SVS, and 8 individual content
eviewers from the ACCF Cardiac Catheterization Com-
ittee and the ACCF Interventional Council. All informa-
ion on reviewer relationships with industry was collected
nd distributed to the writing group and is published in this
ocument (Appendix 2).
This document was approved for publication by the govern-
ng bodies of the ACCF and the AHA and endorsed by the
SE, American Society of Nuclear Cardiology, HRS, SCA,
CAI, SVM, and the SVS.
. Perioperative Therapy
.2. Perioperative Medical Therapy
.2.1. Recommendations for Perioperative
eta-Blocker Therapy (Table 2)
he issue of perioperative beta-blocker therapy was last
ddressed by this committee in the “ACC/AHA 2007
uidelines on Perioperative Cardiovascular Evaluation and
are for Noncardiac Surgery” (3). As outlined in that
ocument, preoperative beta-blocker therapy should be
onsidered in the context of a full evaluation of each
atient’s clinical and surgical risk, including identification of
ctive cardiac conditions that require intensive management
nd may result in delay or cancellation of surgery unless the
urgery is emergent (Table 3). Clinical risk factors for perioperative cardiovascular complications, as used in our
urrent recommendations, are unchanged from the prior
ocument and include the following:
• history of ischemic heart disease;
• history of compensated or prior heart failure;
• history of cerebrovascular disease;
• diabetes mellitus; and
• renal insufficiency (defined in the Revised Cardiac
Risk Index as a preoperative serum creatinine of more
than 2 mg/dL) (9).
The surgery-specific cardiac risk of noncardiac surgery
Table 4) also remains relevant, with an important caveat
eing that limited data are available to guide beta-blocker
se in the presence of newer techniques (e.g., percutaneous
r endovascular vascular procedures) that may be associated
ith lower short-term risk.
The prior document outlined conflicting evidence regard-
ng the efficacy of beta blockers in reducing perioperative
ardiac events, as well as limitations in the evidence base.
hese included the relatively small number of randomized
rials on this issue and the dearth of studies comparing
ifferent beta-blocker agents or providing data to determine
he ideal target population, duration of preoperative titra-
ion, and route of administration. In addition, practical
oncerns, such as how, when, how long, and by whom
erioperative beta-blocker therapy should ideally or practi-
ally be prescribed, remained unaddressed. We advocated
or randomized controlled trials to explore the observation
hat there may be some harm associated with beta-blocker
herapy in low-risk patients (7). Moreover, there was a lack
f data regarding which beta blocker to use perioperatively.
n summary, the best approach on how to reduce cardio-
ascular complications medically during noncardiac surgery
as still unknown. Limitations in the perioperative beta-
locker literature included the following:
• Most trials were inadequately powered.
• Few randomized trials of medical therapy to prevent
perioperative major adverse cardiac events had been
performed.
• Few randomized trials had examined the role of
perioperative beta-blocker therapy, and there was par-
ticularly a lack of trials that focused on high-risk patients.
• Studies to determine the role of beta blockers in
intermediate- and low-risk populations were lacking.
• Studies to determine the optimal type, dose, timing,
duration, and titration of beta blockers were lacking.
• No studies addressed care-delivery mechanisms in the
perioperative setting, identifying how, when, and by
whom perioperative beta-blocker therapy should be
prescribed and monitored.
In addition, as outlined above, there is a paucity of
nformation to help guide beta-blocker use in the setting of
hifts in surgical techniques away from traditional open
rocedures that require general anesthesia and toward less
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Since that guideline was published, important additional
nformation on some but not all of these issues has been
able 2. Updates to Section 7.2.1. Recommendations for Perio
2007 Perioperative Guideline
Recommendations
2009 Periopera
Recom
C
. Beta blockers should be continued in patients
undergoing surgery who are receiving beta
blockers to treat angina, symptomatic
arrhythmias, hypertension, or other ACC/AHA
Class I guideline indications. (Level of
Evidence: C)
1. Beta blockers should
undergoing surgery w
blockers for treatmen
ACCF/AHA Class I gu
drugs. (Level of Evide
. Beta blockers should be given to patients
undergoing vascular surgery who are at high
cardiac risk owing to the finding of ischemia
on preoperative testing. (Level of Evidence: B)
Cl
. Beta blockers are probably recommended for
patients undergoing vascular surgery in whom
preoperative assessment identifies coronary
heart disease. (Level of Evidence: B)
1. Beta blockers titrated
pressure are probabl
undergoing vascular
cardiac risk owing to
the finding of cardiac
testing (4,5). (Level o
. Beta blockers are probably recommended for
patients in whom preoperative assessment
for vascular surgery identifies high cardiac
risk, as defined by the presence of more than
1 clinical risk factor.* (Level of Evidence: B)
2. Beta blockers titrated
pressure are reasona
preoperative assessm
identifies high cardia
presence of more tha
(Level of Evidence: C
. Beta blockers are probably recommended for
patients in whom preoperative assessment
identifies coronary heart disease or high
cardiac risk, as defined by the presence of
more than 1 clinical risk factor,* who are
undergoing intermediate-risk or vascular
surgery. (Level of Evidence: B)
3. Beta blockers titrated
pressure are reasona
preoperative assessm
artery disease or high
the presence of more
who are undergoing
(Level of Evidence: B
Cl
. The usefulness of beta blockers is uncertain
for patients who are undergoing either
intermediate-risk procedures or vascular
surgery, in whom preoperative assessment
identifies a single clinical risk factor.* (Level
of Evidence: C)
1. The usefulness of be
patients who are und
risk procedures or va
preoperative assessm
clinical risk factor in
artery disease.* (Lev
. The usefulness of beta blockers is uncertain
in patients undergoing vascular surgery with
no clinical risk factors who are not currently
taking beta blockers. (Level of Evidence: B)
2. The usefulness of be
patients undergoing
clinical risk factors*
beta blockers (7). (Le
C
. Beta blockers should not be given to patients
undergoing surgery who have absolute
contraindications to beta blockade. (Level of
Evidence: C)
1. Beta blockers should
undergoing surgery w
contraindications to
Evidence: C)
2. Routine administrati
in the absence of do
may be harmful to p
beta blockers who ar
surgery (8). (Level of
Clinical risk factors include history of ischemic heart disease, history of compensated or prior
he Revised Cardiac Risk Index as a preoperative serum creatinine of 2 mg/dL) (9). ACC indicrovided by the POISE (PeriOperative ISchemic Evalua- oion) trial (8), a large, randomized, controlled trial of fixed
igher-dose, extended-release metoprolol started the day of
urgery in more than 8000 patients undergoing noncardiac
urgery, which prompted this focused update on the subject
tive Beta-Blocker Therapy
ocused Update
ations Comments
ntinued in patients
e receiving beta
onditions with
e indications for the
)
2007 recommendation remains current in
2009 update with revised wording.
Deleted/combined recommendation (class of
recommendation changed from I to IIa for
patients with cardiac ischemia on
preoperative testing).
a
art rate and blood
mmended for patients
y who are at high
ary artery disease or
mia on preoperative
ence: B)
Modified/combined recommendation (wording
revised and class of recommendation
changed from I to IIa for patients with cardiac
ischemia on preoperative testing).
art rate and blood
r patients in whom
or vascular surgery
as defined by the
linical risk factor.*
Modified recommendation (level of evidence
changed from B to C).
art rate and blood
r patients in whom
entifies coronary
iac risk, as defined by
1 clinical risk factor,*
ediate-risk surgery (6).
2007 recommendation remains current in
2009 update with revised wording.
b
kers is uncertain for
g either intermediate-
surgery in whom
entifies a single
sence of coronary
vidence: C)
2007 recommendation remains current in
2009 update with revised wording.
kers is uncertain in
ar surgery with no
re not currently taking
Evidence: B)
2007 recommendation remains current in
2009 update.
I
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ve absolute
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2007 recommendation remains current in
2009 update.
igh-dose beta blockers
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ergoing noncardiac
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New recommendation
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eduction in primary cardiac events such as cardiovascular
eath, myocardial infarction (MI), and cardiac arrest with
erioperative beta-blocker therapy. However, that benefit
as offset by an increased risk of stroke and total mortality,
hich suggests that routine administration of high-dose
eta blockers in the absence of dose titration is not useful
nd may be harmful to beta-blocker–naïve patients under-
oing surgery.
able 3. Active Cardiac Conditions for Which the Patient
hould Undergo Evaluation and Treatment Before Noncardiac
urgery (Class I, Level of Evidence: B)*
Condition Examples
nstable coronary
syndromes
Unstable or severe angina† (CCS class III
or IV)‡
Recent MI§
ecompensated HF (NYHA
functional class IV;
worsening or new-onset HF)
ignificant arrhythmias High-grade atrioventricular block
Mobitz II atrioventricular block
Third-degree atrioventricular heart block
Symptomatic ventricular arrhythmias
Supraventricular arrhythmias (including atrial
fibrillation) with uncontrolled ventricular
rate (heart rate 100 bpm at rest)
Symptomatic bradycardia
Newly recognized ventricular tachycardia
evere valvular disease Severe aortic stenosis (mean pressure
gradient 40 mm Hg, aortic valve area
1.0 cm2, or symptomatic)
Symptomatic mitral stenosis (progressive
dyspnea on exertion, exertional
presyncope, or HF) or MVA 1.5 cm2
The presence of 1 or more of these conditions mandates intensive management and may result
n delay or cancellation of surgery unless the surgery is emergent (3). †According to Campeau
10). ‡May include “stable” angina in patients who are unusually sedentary. §The American
ollege of Cardiology National Database Library defines recent MI as 7 days but 1 month
within 30 days).
bpm indicates beats per minute; CCS, Canadian Cardiovascular Society; HF, heart failure; MI,
yocardial infarction; MVA, mitral valve area; and NYHA, New York Heart Association.
able 4. Cardiac Risk* Stratification for Noncardiac
urgical Procedures
Risk Stratification Procedure Examples
ascular (reported cardiac risk often 5%) Aortic and other major
vascular surgery
Peripheral vascular surgery
ntermediate (reported cardiac risk
generally 1% to 5%)
Intraperitoneal and
intrathoracic surgery
Carotid endarterectomy
Head and neck surgery
Orthopedic surgery
Prostate surgery
ow† (reported cardiac risk generally 1%) Endoscopic procedures
Superficial procedure
Cataract surgery
Breast surgery
Ambulatory surgeryb
Combined incidence of cardiac death and nonfatal myocardial infarction. †These procedures do
ot generally require further preoperative cardiac testing (3).Current studies suggest that beta blockers reduce periop-
rative ischemia and may reduce the risk of MI and
ardiovascular death in high-risk patients. However, routine
dministration of higher-dose long-acting metoprolol in
eta-blocker–naïve patients on the day of surgery and in the
bsence of dose titration is associated with an overall
ncrease in mortality. How should clinicians reconcile these
onflicting data? Importantly, the POISE results (8) do not
ddress continuation of beta blockers in patients undergoing
urgery who are receiving beta blockers for ACCF/AHA
lass I guideline indications; therefore, this continues to be
Class I recommendation for beta-blocker therapy in the
resent focused update. In addition, available evidence
uggests but does not definitively prove that when possible
nd where indicated, beta blockers should be started days to
eeks before elective surgery. The dose should be titrated
erioperatively to achieve adequate heart rate control to
ncrease the likelihood that the patient will receive the
enefit of beta blockade, while seeking to minimize the
onsiderable risks of hypotension and bradycardia seen in
OISE (see Section 7.2.1.4). Titrated rate control with beta
lockers should continue during the intraoperative and
ostoperative period, if possible, to maintain a heart rate of
0 to 80 bpm in the absence of hypotension, because this
egimen has demonstrated efficacy (5,11). However, routine
dministration of high-dose beta blockers in the absence of
ose titration for patients undergoing noncardiac surgery is
ot useful, may be harmful, and cannot be advocated, which
esults in a new Class III recommendation for this practice.
he committee continues to advocate for additional studies
o address remaining issues regarding the safety and efficacy
f beta-blocker therapy as outlined above.
.2.1.1. EVIDENCE ON EFFICACY OF BETA-BLOCKER THERAPY
tudies reviewed that provide primary data regarding the
fficacy and safety of beta-blocker therapy in noncardiac
urgery are summarized in Appendix 3. A more detailed
iscussion of these studies and of systematic reviews and
eta-analyses incorporating these data is provided in the
ections that follow. Several randomized trials examined the
ffect of perioperative beta blockers on cardiac events
urrounding surgery. Poldermans et al. (5) examined the
ffect of bisoprolol on patients undergoing vascular surgery
nd in patients at high risk for perioperative cardiac com-
lications who were scheduled for vascular surgery. Of 846
atients with risk factors for cardiac disease, 173 were found
o have new regional wall-motion abnormalities with stress
n dobutamine stress echocardiography. Of these patients,
1 were excluded from further study owing to large areas (5
r more segments) of regional wall-motion abnormalities on
obutamine stress echocardiography or because they were
lready taking beta blockers. The remaining 112 high-risk
atients were randomized to standard care or bisoprolol
tarted at least 7 days before surgery and titrated to maintain
eart rate less than 60 bpm preoperatively and less than 80
pm intraoperatively and postoperatively. The rates of
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November 24, 2009:2102–28 Focused Update on Perioperative Beta Blockadeardiac death (3.4% versus 17%; p0.02) and nonfatal MI
0% versus 17%; p0.001) were lower for the bisoprolol
roups than for the placebo groups, respectively. Impor-
antly, owing to the unblinded design and the inclusion of
nly high-risk patients in this study, the results cannot be
eneralized to all patients undergoing noncardiac surgery.
Boersma et al. (4) subsequently reanalyzed the total
ohort of 1351 consecutive patients considered for enroll-
ent in the aforementioned randomized trial of bisoprolol.
orty-five patients had perioperative cardiac death or non-
atal MI. Eighty-three percent of the 1351 patients had
ewer than 3 clinical risk factors, and in this subgroup,
atients taking beta blockers had a lower risk of cardiac
omplications (0.8% [2 of 263]) than those not taking beta
lockers (2.3% [20 of 855]). In patients with 3 or more risk
actors (17%), those taking beta blockers who had a dobut-
mine stress echocardiography examination that demon-
trated 4 or fewer segments of new wall-motion abnormal-
ties had a significantly lower incidence of cardiac
omplications (2.3% [2 of 86]) than those not receiving
eta-blocker therapy (9.9% [12 of 121]). However, among
he small group of patients with more extensive ischemia on
obutamine stress echocardiography (5 or more segments),
here was no difference in the incidence of cardiac events (4
f 11 for those taking beta blockers versus 5 of 15 for those
ot taking beta blockers). Therefore, beta-blocker therapy
as beneficial in all but the subset of patients with more
xtensive ischemia. Nevertheless, one must be cautious
bout inferring a class effect from this observation.
Mangano et al. (12) reported on 200 patients undergoing
eneral surgery who were randomized to a combination of
ntravenous and oral atenolol versus placebo for 7 days.
lthough they found no difference in in-hospital perioper-
tive deaths (4 of 99 versus 2 of 101) or MI, they reported
ignificantly fewer episodes of ischemia by Holter monitor-
ng in the atenolol group than in the placebo group (24%
ersus 39%, respectively; p0.03). They then conducted
ollow-up on these patients after discharge and documented
ewer deaths in the atenolol group over the subsequent 6
onths (1% versus 10%; p0.001). Overall, 13 of 99
atients in the atenolol group and 23 of 101 patients in the
lacebo group died when both in-hospital and postdis-
harge events were considered. It is unclear why such a brief
ourse of therapy could exert such a delayed effect, and the
tudy did not control for other medications given either
efore or after surgery. Use of angiotensin-converting en-
yme inhibitors and beta blockers postoperatively differed
ignificantly between the study groups.
More recent randomized trials have examined beta block-
de for the prevention of perioperative cardiac complica-
ions during noncardiac surgery. Juul et al. (13) randomized
21 subjects with diabetes mellitus who were undergoing a
ange of noncardiac operations to either 100 mg of
xtended-release metoprolol or placebo in the DIPOM
DIabetic POstoperative Mortality and morbidity) study.
here was no significant difference in the primary compos- tte outcome of time to all-cause mortality, MI, unstable
ngina, or congestive heart failure (CHF) (21% versus 20%)
n patients randomized to higher-dose metoprolol versus
lacebo. Among those randomized, an equal number of
eaths (16%) were observed in both groups. MI rates were
ot reported separately. Yang et al. (14) reported a study of
96 subjects undergoing major vascular surgery who were
andomized to dose-adjusted metoprolol or placebo. Exclu-
ions in that study included those already taking a beta
locker. They reported similar MI rates (7.7% versus 8.4%;
0.87) and death rates (0% versus 1.6%) at 30 days in the
eta-blocker and placebo groups, respectively. These were
ot noninferiority analyses but rather simply negative study
esults. Most importantly for the purposes of these guide-
ines, the patients included in the studies by Juul et al. (13)
nd Yang et al. (14) were patients with diabetes in 1 study
nd patients undergoing major vascular surgery in the other,
ho undoubtedly represent a heterogeneous risk group
ithout documented coronary artery disease.
Additional studies have examined the use of perioperative
eta blockers but have used surrogate end points such as
lectrocardiographic ST changes, were not randomized, did
ot use general anesthesia, or had limited power to detect
ifferences in cardiac events. Stone et al. (15) randomized a
roup of patients with mild hypertension who underwent
redominantly (58%) vascular surgery either to oral beta
lockers 2 hours before surgery or to standard care. Control
ubjects had a higher frequency (28%) of ST-segment
epression (on intraoperative monitoring, as reported by the
uthors) than treated patients (2%). In a nonrandomized
tudy, Pasternack et al. (16) gave oral metoprolol immedi-
tely before abdominal aortic aneurysm repair surgery,
ollowed postoperatively by intravenous metoprolol. Only
% of patients experienced an acute MI compared with 18%
or matched control subjects. Pasternack et al. (17) subse-
uently reported fewer episodes of intraoperative ischemia
n patients treated with oral metoprolol before peripheral
ascular surgery than in untreated patients. Yeager et al. (18)
eported a case-control analysis of their experience with
erioperative MI during vascular surgery, comparing 53
ndex cases of perioperative MI with 106 matched control
ubjects. They found a strong association of beta-blocker
se with a decreased likelihood of MI (OR 0.43; p0.01).
n 26 vascular surgery patients with documented preopera-
ive ischemia who were randomized to a protocol of heart
ate suppression with intravenous esmolol compared with
tandard care, Raby et al. (19) demonstrated that the
smolol group had fewer episodes of ischemia than control
ubjects (33% versus 73%; p0.055).
Zaugg et al. (20) randomized elderly noncardiac surgery
atients to preoperative and postoperative atenolol titrated
o heart rate, intraoperative atenolol titrated to heart rate, or
o beta blockers and detected no episodes of intraoperative
yocardial ischemia, electrocardiographic changes consis-
ent with MI, or death in any group. Three of 19 patients in
he no beta-blocker group developed significant elevations
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ompared with none of 40 patients who received 1 of the
tenolol regimens. In a follow-up study, Zaugg et al. (21)
andomized 219 patients undergoing spinal, rather than
eneral, anesthesia to bisoprolol or placebo. The composite
utcome of cardiovascular mortality, nonfatal MI, unstable
ngina, CHF, and cerebrovascular event was not signifi-
antly different over the 1-year follow-up period. Interest-
ngly, adrenergic-receptor genotype was associated with
utcome in this study, which raises the possibility that
enetic heterogeneity may be another important determi-
ant of outcome. Brady et al. (22) randomized patients
ndergoing elective vascular surgery to either metoprolol 50
g twice a day or placebo, from admission to the hospital
ntil 7 days after surgery. They found no difference in
ardiovascular events, which included MI, unstable angina,
entricular tachycardia, and stroke. This trial may have been
nderpowered (n103) to identify a difference in outcomes,
articularly hard outcomes of death and MI. Also, by trial
esign, therapy was initiated the day before vascular surgery,
nd it is quite possible that those randomized to metoprolol
eceived incomplete beta blockade in the early perioperative
eriod.
Perioperative beta-blocker therapy has also been reviewed
n several meta-analyses and in a very large cohort popula-
ion study before publication of the recent POISE trial (8).
uerbach and Goldman (23) undertook a review of this
opic in 2002. They reported on a MEDLINE search and
iterature review of 5 studies (all 5 studies are included in
able 12 in the full-text guideline [3]). They calculated an
NT on the basis of these studies of 2.5 to 6.7 to see
mprovement in measures of myocardial ischemia and 3.2 to
.3 in studies that reported a significant impact of beta
lockers on cardiac or all-cause mortality. They concluded
hat the literature supports a benefit of beta blockers on
ardiac morbidity and mortality.
A systematic review of the perioperative medical therapy
iterature by Stevens et al. (24) for noncardiac surgery
ncluded the results of 11 trials using beta blockers for
erioperative therapy. These authors concluded that beta
lockers significantly decreased ischemic episodes during
nd after surgery. Beta blockers significantly reduced the
isk of nonfatal MI; however, the results became nonsignif-
cant if the 2 most positive trials were eliminated. Likewise,
he risk of cardiac death was significantly decreased with
eta-blocker usage. These authors incorporated studies not
onsidered in other meta-analyses, including studies that
ere not blinded. Results to be quantified were limited to
hose in the 30-day perioperative period. The authors also
eported a direct relationship between the prevalence of
rior MI and the magnitude of risk reduction observed with
eta-blocker therapy, which suggests that higher risk con-
ers greater benefit. The NNT to prevent perioperative
schemia was 8 subjects, the NNT to prevent MI was 23,
nd 32 patients had to be treated to prevent cardiac death.
hese authors pointed out that given the observation that 0igh-risk patients appeared to receive all the benefit, the
arget population for beta-blocker therapy is not clear. They
lso highlighted that schedules of beta-blocker administra-
ion varied significantly among the reported studies, and
hey acknowledged the potential for a single, large, strongly
ositive study to skew the results of this meta-analysis (24).
In contrast, Devereaux et al. (25) published their opinion
aper on the clinical evidence regarding the use of beta-
locker therapy in patients undergoing noncardiac surgery
or the purpose of preventing perioperative cardiac compli-
ations. They expressed the opinion that the literature
upporting the use of beta blockers during noncardiac
urgery is modest at best and is based on a few small,
nblinded studies with a focused patient population. In a
eview of the literature in 2005, Devereaux et al. (26)
iscussed 22 studies that randomized 2437 patients under-
oing noncardiac surgery to beta-blocker therapy or pla-
ebo. The POBBLE (PeriOperative Beta-BLockadE) study
22) was not included in this review. They found no
tatistically significant benefit with regard to any of the
ndividual outcomes and a “nominally” statistically signifi-
ant benefit (RR 0.44, 99% confidence interval [CI] 0.16 to
.24) for the composite outcome of cardiovascular mortality,
onfatal MI, and nonfatal cardiac arrest. The authors
elieved that these data were inadequate to draw conclu-
ions without a larger, controlled study. This review, how-
ver, included a wide variety of studies, patient populations,
nd beta-blocker regimens. Many of the studies described
nly a single or double dose of beta blockers preoperatively
r at induction of anesthesia. Many of the data, therefore,
o not pertain to perioperative beta blockade for the purpose
f cardiac risk reduction or are focused on a low-risk
opulation. Additionally, the largest studies included, those
eported by Miller et al. (27) and preliminary data from
ang et al. (14), which together account for almost as many
ubjects as all the other studies combined, may not have
een appropriate to include in this analysis. The first, by
iller et al. (27), was a study of a single intravenous dose of
eta blocker for the purpose of blood pressure control
uring intubation, not reduction of perioperative events. It
ncluded follow-up only to the point of discharge from the
ecovery room. The second was Yang et al. (14), an abstract
f a paper that has now been published. The studies
ncluded in this review also varied widely in length of
ollow-up.
McGory et al. (28) performed a meta-analysis of 6
andomized trials of perioperative beta blockade and con-
luded that therapy was associated with significant reduc-
ions in perioperative myocardial ischemia (from 33% to
5%), MI, cardiac mortality, and long-term cardiac mortal-
ty (from 12% to 2%). These authors used the combined
ata to derive ORs and CIs for several outcomes. For
erioperative overall mortality, the OR for beta-blocker
herapy was 0.52 (95% CI 0.20 to 1.35), and for perioper-
tive cardiac mortality, the OR was 0.25 (95% CI 0.07 to
.87). Neither the POBBLE (22) study nor the unpublished
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November 24, 2009:2102–28 Focused Update on Perioperative Beta Blockadendings included in Devereaux et al.’s article were included,
hich explains the marked difference in findings from the
ther meta-analysis.
More recently, Wiesbauer et al. (29) published a system-
tic review of randomized trials through 2005 of perioper-
tive beta-blocker use in both cardiac and noncardiac
urgery. The authors concluded that beta blockers reduced
erioperative arrhythmias and myocardial ischemia, but they
ere unable to show an effect on mortality or perioperative
I. A cohort study by Lindenauer et al. (7) reviewed
dministrative records from more than 600 000 patients
ndergoing noncardiac surgery at 329 hospitals in the
nited States. Participant hospitals in this cohort study
ere members of a consortium database measuring quality
f care and healthcare use. These authors evaluated all
oncardiac surgical cases and compared those who received
eta blockers within the first 2 days of hospitalization with
hose who did not. The authors used propensity–score-
atching techniques in an attempt to reduce confounding
nd selection bias. These authors found that for a Revised
ardiac Risk Index score (9) of 3 or more (based on the
resence of history of ischemic heart disease, cerebrovascu-
ar disease, renal insufficiency, diabetes mellitus, or a patient
ndergoing high-risk surgery), patients who received beta
lockers were significantly less likely to die while in the
ospital. This was not true for those with a Revised Cardiac
isk Index of 2, l, or 0. Those with a risk index of 0 were
ore likely to die in the hospital if given a beta blocker on
ay 1 or day 2 of hospitalization. This study was retrospec-
ive and not randomized and is therefore subject to potential
ias. This is particularly true in terms of reporting bias,
ecause the documentation was based entirely on adminis-
rative data sets, with arbitrary definitions of “on” or “off”
erioperative beta blockers that were based solely on hospi-
al day of use. Nonetheless, there appears to be an associa-
ion between improved outcomes and the use of beta
lockers in clinically high-risk patients, whereas lower-risk
atients had worse outcomes, which raises concerns regard-
ng the routine use of beta blockers perioperatively in
ower-risk patients.
One observational cohort study examined the question of
hich beta blocker may be best for perioperative medical
herapy. Redelmeier et al. (30) retrospectively reviewed
rescription records and administrative data related to
lective surgery in Ontario, Canada, from April 1992 to
pril 2002. They limited their analysis to patients older
han 65 years of age who were receiving prescriptions for
ither atenolol or short-acting metoprolol before and after
urgery (although actual beta-blocker use perioperatively
as not ascertained) and identified 37 151 subjects. A total
f 1038 either had a perioperative MI or died, and the rate
f MI or death was significantly lower among those patients
eceiving atenolol than among those given metoprolol (2.5%
ersus 3.2%; p0.001). This difference persisted even after
djustment for demographic, clinical, and surgical factors.
he inclusion of other long-acting beta blockers in the wnalysis yielded an identical risk reduction. Although lim-
ted by several methodological issues, these data suggest that
ong-acting beta blockade (when therapy is initiated before
urgery) might be superior to short-acting beta blockade,
ut clinical trial evaluation is awaited to confirm this.
.2.1.1.1. RECENT DATA REGARDING PERIOPERATIVE BETA-BLOCKER THERAPY
NEW SECTION). Since the publication of the 2007 update, the
OISE trial investigators have published the results of their
tudy (8). Patients were randomly assigned to receive
xtended-release metoprolol succinate or placebo starting 2
o 4 hours before surgery and continued for 30 days with a
rimary end point of a composite of cardiovascular death,
onfatal MI, and nonfatal cardiac arrest. Patients were
ligible if they were undergoing noncardiac surgery, were 45
ears or older, had an expected length of hospital stay of at
east 24 hours, and fulfilled any 1 of the following criteria:
istory of coronary artery disease; peripheral vascular dis-
ase; stroke; hospitalization for CHF within previous 3
ears; undergoing major vascular surgery; or any 3 of 7 risk
riteria (undergoing intrathoracic or intraperitoneal surgery,
istory of CHF, transient ischemic attack, diabetes mellitus,
erum creatinine more than 175 micromoles/L, age older
han 70 years, or undergoing emergency or urgent surgery).
atients who were previously receiving a beta blocker or
ho had coronary artery bypass graft surgery in the preced-
ng 5 years and no cardiac ischemia since that time were
xcluded. Patients received the first dose of the study drug
metoprolol succinate 100 mg or placebo) 2 to 4 hours before
urgery. Drug administration in the study required a heart
ate of 50 bpm or higher and a systolic blood pressure of 100
m Hg or greater; these parameters were checked before
ach administration. If at any time during the first 6 hours
fter surgery heart rate was 80 bpm or more and systolic
lood pressure was 100 mm Hg or higher, patients received
heir first postoperative dose (extended-release metoprolol
00 mg or matched placebo) orally. If the study drug was
ot given during the first 6 hours, patients received their
rst postoperative dose at 6 hours after surgery. Twelve
ours after the first postoperative dose, patients started
aking oral extended-release metoprolol 200 mg or placebo
very day for 30 days. If a patient’s heart rate was consis-
ently below 45 bpm or their systolic blood pressure dropped
elow 100 mm Hg, study drug was withheld until their
eart rate or systolic blood pressure recovered; the study
rug was then restarted at 100 mg once daily. Patients
hose heart rate was consistently 45 to 49 bpm and whose
ystolic blood pressure exceeded 100 mm Hg delayed taking
he study drug for 12 hours. Patients who were unable to
ake medications orally received the study drug by intrave-
ous infusion (slow infusion of 15 mg of study drug over 60
inutes or rapid infusion of 5 mg over 2 minutes every 5
inutes up to a total of 15 mg as long as hemodynamic
riteria were met) until they could resume oral medications.
The final analysis included 8351 patients from 190
ospitals in 23 countries. Several hundred more participants
ere excluded because of fraudulent activity at their sites. A
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Focused Update on Perioperative Beta Blockade November 24, 2009:2102–28otal of 8331 patients (99.8%) completed the 30-day follow-
p. Fewer patients in the metoprolol group than in the
lacebo group reached the primary end point of cardiovas-
ular death, nonfatal MI, and nonfatal cardiac arrest (244
5.8%] in the metoprolol group versus 290 [6.9%] in the
lacebo group; HR 0.84, 95% CI 0.70 to 0.99; p0.0399).
ewer patients in the metoprolol group than in the placebo
roup had an MI (176 [4.2%] versus 239 [5.7%]; HR 0.73,
5% CI 0.60 to 0.89; p0.0017). However, more people
eceiving metoprolol died than did individuals receiving
lacebo (HR 1.33, 95% CI 1.03 to 1.74; p0.0317); the
aplan-Meier mortality estimates started separating on day
0. The only reported cause of death for which there was a
ignificant difference between groups was sepsis or infection,
hich was more common among patients allocated to
etoprolol. More patients in the metoprolol group than in
he placebo group had a stroke (41 [1.0%] versus 19 [0.5%]
atients; HR 2.17, 95% CI 1.26 to 3.74; p0.0053). Most
atients who had a nonfatal stroke subsequently required
elp to perform everyday activities or were incapacitated.
ultiple predefined subgroup analyses were performed,
lthough the study was underpowered to detect modest
ifferences in subgroup effects. The cohort that developed
linically significant hypotension had the largest population-
ttributable risk for death and the largest intraoperative or
ostoperative risk for stroke. In the wake of POISE, a
eta-analysis of trials investigating the use of beta blockers
round the time of noncardiac surgery and incorporating the
OISE results was published (31). The authors found that
eta blockers were associated with a significant reduction in
onfatal MI (OR 0.65) and ischemia (OR 0.36) at the
xpense of an increased risk of stroke (OR 2.01), as well as
radycardia and hypotension. As the largest of the included
rials by far, these results are largely driven by the POISE
esults. The results point to a need to understand more fully
he causes for the increased risk of stroke and death seen in
OISE and their relation to the potential hemodynamic
ffects of beta blockade. Because of limitations inherent in
eta-analysis, these analyses could not be adjusted for type
nd duration or dosage of beta blockers used in treatment
rotocols.
Several nonrandomized studies have also been published.
aafarani et al. (32) published a retrospective, single-center
xperience assessing outcomes in those who received beta
lockers perioperatively (n238) compared with a control
roup (n408) that did not. In this study, unlike POISE,
eta-blocker use was associated with an increased risk of MI
t 30 days (2.94% versus 0.74%; p0.03) and death (2.52%
ersus 0.25%; p0.007), and patients who died had signif-
cantly higher preoperative heart rates, but these data are
ifficult to interpret in light of methodological limitations.
atyal et al. (33) analyzed retrospective data from 960
atients (594 men, 366 women) undergoing primarily in-
rainguinal vascular surgery. They reported that use of beta
lockers was associated with a lower risk of adverse outcome
including MI, CHF, death, significant arrhythmia, and nenal failure) in men (12.6% versus 18.9%; p0.04) but not
n women (17.8% versus 13.7%; p0.37), which raises the
uestion of sex difference in response to perioperative beta
lockade.
Finally, the results of a large (n1066), randomized,
ontrolled trial of bisoprolol and fluvastatin use in
ntermediate-risk patients undergoing noncardiac surgery
DECREASE IV) were presented at the 2008 American
eart Association Annual Scientific Sessions and were
ublished recently (6). Patients were enrolled who were at
east 40 years of age, were scheduled for elective noncardiac
urgery, and had an estimated risk of perioperative death
nd MI of 1% to 6%. Exclusion criteria included the use of
eta blockers; a contraindication for beta blocker use; the
se of statins before randomization; a contraindication for
tatin use; unstable coronary heart disease or evidence of
-vessel disease or left main disease; elevated cholesterol
ccording to the National Cholesterol Consensus; emer-
ency surgery; inability or unwillingness to provide written
nformed consent; and previous participation in the same
rial. Participants were randomized according to an open-
abel, factorial design to 1) beta-blocker therapy (bisopro-
ol), 2) statin (fluvastatin XL 80 mg daily), 3) a combination
f a beta blocker and a statin (bisoprolol and fluvastatin), or
) neither a beta blocker nor a statin (control group). By
esign, study medication could be started up to the day of
urgery (median 34 days before the procedure, interquartile
ange 21 to 53 days) and was to be continued until 30 days
fter surgery. The starting dose of bisoprolol was 2.5 mg
rally per day if resting heart rate was higher than 50 bpm.
uring hospitalization, resting heart rate was evaluated on a
aily basis, and drug dose was modified in steps of 1.25 or
.5 mg per day, up to a maximum dose of 10 mg, aiming for
heart rate of 50 to 70 bpm. The primary efficacy end point
as a composite of cardiac death and nonfatal MI until 30
ays after surgery. The study was terminated early owing to
low enrollment linked to widespread use of 1 or both types
f medications in the population screened. Patient charac-
eristics were as follows: median age 64 years; 60% male;
1% with diabetes mellitus; 6% with angina pectoris; 5%
ith prior MI; and 4% with prior stroke. The most common
ypes of surgery were general (39%), urological (19%),
rthopedic (16%), and ear-nose-throat (12%). Patients ran-
omized to bisoprolol (n533) had a lower incidence of
erioperative cardiac death and nonfatal MI than those who
id not receive bisoprolol (2.1% versus 6.0% events; HR
.34, 95% CI 0.17 to 0.67; p0.002). Ischemic stroke
ccurred in 7 patients (0.7%), of whom 4 (0.8%) were
andomized to bisoprolol treatment and 3 (0.6%) were
andomized to the group that did not receive bisoprolol
p0.68). In total, 3 patients (0.6%) randomized to biso-
rolol reached 1 other beta–blocker-related safety end point
heart failure, clinically significant bradycardia, or hypoten-
ion) compared with 2 patients (0.4%) in the group that did
ot receive bisoprolol (p0.65). The authors also reported a
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ined, with no difference between treatment groups.
This research demonstrated a cardioprotective effect of
erioperative beta-blocker use in the intermediate-risk
roup, without an increased incidence of perioperative
troke or mortality, although power for these end points was
imited. Importantly, beta blockers were generally started
ell in advance of surgery and were titrated to heart rate
tarting at a low dose (6).
.2.1.2. TITRATION OF BETA BLOCKERS
eta-blocker therapy is commonly used to reduce adverse
ardiac events in conditions such as MI and CHF. Titration
f the dose is a well-recognized part of using this class of
edication. For example, the “ACC/AHA 2007 Guidelines
or the Management of Patients With Unstable Angina/
on–ST-Elevation Myocardial Infarction” (34) and the
ACC/AHA Guidelines for the Management of Patients
ith ST-Elevation Myocardial Infarction” (35) recom-
end dose titration of beta blockers to a goal heart rate of
0 to 60 bpm. Titration to goal heart rate in this case is
ssociated with more benefit than the fixed-dose application
f the medication alone. Cucherat (36) evaluated 17 trials of
eta blockers in patients with MI that reported change in
eart rate, showing that each 10-bpm reduction in the heart
ate is estimated to reduce the RR of cardiac death by 30%.
n patients with MI, the use of fixed, higher-dose therapy
as associated with increases in cardiogenic shock that offset
eductions in reinfarction and ventricular fibrillation (37). In
HF, the “ACC/AHA 2005 Guideline Update for the
iagnosis and Management of Chronic Heart Failure in
he Adult” (38) also suggested that beta blockers should be
itrated up to high-dose therapy in patients who could
olerate these doses. Recent data suggest that high-dose
herapy, in patients who tolerate the dose, reduces event
ates more than low-dose therapy (5).
Similarly, in the management of perioperative patients,
xed-dose beta-blocker administration has not shown suf-
cient benefit to warrant routine use. POISE, as the largest
rial to date, and the only trial with enough power to
onfirm a null result, makes this clear. Several potential
roblems can arise from a fixed-dose management strategy.
irst, fixed-dose strategies cannot account for the variability
n response to medications within a population and may
rovide doses that are inadequate for some patients, ade-
uate for some, and clearly too much for others, as evi-
enced by increased hypotension and bradycardia. Second,
ong-acting oral medications may not provide the flexibility
equired for the dynamic postoperative clinical condition.
hird, fixed-dose regimens presuppose a constant require-
ent for beta blockade in the postoperative setting. Small
hysiological trials have made clear that sympathetic ner-
ous system tone increases after operation and returns to
aseline within 4 to 5 days (39), which suggests variation in
he required dose within individual patients. tIn contrast to the fixed-dose studies, beta-blocker dose
itration may provide benefit in high-risk patients. Feringa
t al. (40) performed an observational cohort study of 272
ascular surgery patients. The beta-blocker dose was con-
erted to a percentage of the maximum recommended
herapeutic dose. In multivariable analysis, higher beta-
locker doses (per 10% increase) were significantly associ-
ted with a lower incidence of myocardial ischemia (HR
.62, 95% CI 0.51 to 0.75), troponin T release (HR 0.63,
5% CI 0.49 to 0.80), and long-term mortality (HR 0.86,
5% CI 0.76 to 0.97). Higher heart rates during electrocar-
iographic monitoring (per 10-bpm increase) were signifi-
antly associated with an increased incidence of myocardial
schemia (HR 2.49, 95% CI 1.79 to 3.48), troponin T
elease (HR 1.53, 95% CI 1.16 to 2.03), and long-term
ortality (HR 1.42, 95% CI 1.14 to 1.76). An absolute
ean perioperative heart rate lower than 70 bpm was
ssociated with the best outcome.
Poldermans et al. (11) randomly assigned 770 intermediate-
isk patients to cardiac stress testing (n386) or no testing
n384). All patients received beta blockers, and the
eta-blocker dose was adjusted preoperatively to achieve a
esting heart rate of 60 to 65 bpm. In patients with
schemia, physicians aimed to control heart rate below the
schemic threshold. Patients assigned to no testing had a
imilar incidence of the cardiac events as those assigned to
esting. Patients with a heart rate lower than 65 bpm had
ower risk than the remaining patients (1.3% versus 5.2%;
R 0.24, 95% CI 0.09 to 0.66; p0.003). The authors
oncluded that cardiac testing can safely be omitted in
ntermediate-risk patients, provided that beta blockers
imed at tight heart rate control are prescribed. The
mportance of heart rate control in reducing perioperative
yocardial ischemia is further supported by a study by Raby
t al. (19).
Meta-analyses addressing this subject have had mixed
esults. Beattie et al. (41) identified 10 trials enrolling 2176
ubjects. Trials associated with an estimated maximal heart
ate of lower than 100 bpm showed cardioprotection for MI
OR 0.23, 95% CI 0.08 to 0.65; p0.005), whereas those
ith higher maximal heart rates did not (OR 1.17, 95% CI
.79 to 1.80; p0.43). Biccard et al. (42) identified 8 studies
f perioperative beta blockade around the time of noncar-
iac surgery and found no correlation between heart rate
nd cardiac complications at 30 days, although postopera-
ive heart rate was not a primary end point in these studies.
verall, available evidence suggests that beta blockers, if
sed, should be appropriately titrated throughout the pre-
perative, intraoperative, and postoperative period to
chieve effective heart rate control while avoiding frank
ypotension and bradycardia.
.2.1.3. WITHDRAWAL OF BETA BLOCKERS
eta-blocker withdrawal has been associated with an in-
reased risk of MI and chest pain. Psaty et al. (43) showed
hat hypertensive patients who stopped taking their beta
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vents associated with coronary heart disease (RR 4.5, 95%
I 1.1 to 18.5). More recently, Teichert et al. (44) showed
hat selective beta-blocker discontinuation resulted in a
igher risk of MI in the first 30 days (RR 2.70, 95% CI 1.06
o 6.89) and between 30 and 180 days (RR 2.44, 95% CI
.07 to 5.59) after cessation, although older data from Croft
t al. (45) suggest the short-term risk of discontinuation
uring MI is modest and does not result in a significant
ncrease in infarct size or worsened in-hospital outcomes.
Concerns regarding the discontinuation of beta-blocker
herapy in the perioperative period have existed for several
ecades (46). Shammash et al. (47) retrospectively studied a
otal of 140 patients who received beta blockers preopera-
ively. Mortality in the 8 patients who had beta blockers
iscontinued postoperatively (50%) was significantly greater
han in the 132 patients in whom beta blockers were
ontinued (1.5%; OR 65.0; p0.001). Hoeks et al. (48)
tudied 711 consecutive peripheral vascular surgery patients.
fter adjustment for potential confounders and the propen-
ity of its use, continuous beta-blocker use remained signif-
cantly associated with a lower 1-year mortality than among
onusers (HR 0.4, 95% CI 0.2 to 0.7). In contrast, beta-
locker withdrawal was associated with an increased risk of
-year mortality compared with nonusers (HR 2.7, 95% CI
.2 to 5.9).
Thus, although data are limited, perioperative beta-
locker withdrawal should be avoided unless necessary. As
oted in the recommendations, continuation of beta-
locker therapy in the perioperative period is a Class I
ndication, and accumulating evidence suggests that titra-
ion to maintain effective heart rate control while avoiding
rank hypotension and bradycardia should be the goal.
.2.1.4. RISKS AND CAVEATS (NEW SECTION)
erioperative beta blockade is associated with risk. All of the
reviously discussed studies have incorporated lower limits
f heart rate and blood pressure with regard to holding or
iscontinuing the study medication. In the POISE trial, the
ral study medication was held if the heart rate was
onsistently below 45 bpm or the systolic blood pressure was
elow 100 mm Hg (8). If a patient’s heart rate was
onsistently 45 to 49 bpm, there was a delay of 12 hours in
dministering the study drug. If the patient was on an
ntravenous infusion, the study medication was held if the
atient’s heart rate dropped below 50 bpm or systolic blood
ressure dropped to below 100 mm Hg. Similarly, Polder-
ans et al. (5) held beta-blocker medication if the heart rate
as lower than 50 bpm or the systolic blood pressure was
ower than 100 mm Hg. Several meta-analyses have exam-
ned the rates of bradycardia and hypotension. Stevens et al.
24) reported an OR of 3.76 (95% CI 2.45 to 5.77; number
eeded to harm6) for bradycardia, although the definition
f bradycardia varied from study to study. In the more
ecent meta-analysis, the risk ratio for postoperative brady-
ardia was 2.22 (95% CI 1.50 to 3.29), and the risk ratio for fradycardia that required treatment was 2.34 (95% CI 1.62
o 3.37) (49). Postoperative hypotension was also signifi-
ant, with a risk ratio of 1.29 (95% CI 1.10 to 1.51). Beattie
t al. (41) analyzed 10 randomized trials with 2176 patients
nd found that perioperative beta blockade was associated
ith an increased incidence of bradycardia (OR 3.49, 95%
I 2.4 to 5.9) and CHF (OR 1.68, 95% CI 1.00 to 2.8).
mportantly, administration of beta blockers did not reliably
ecrease HRs in all patients. In the POISE trial (8), the HR
n the metoprolol group for clinically significant hypoten-
ion was 1.55 (95% CI 1.38 to 1.74), and the HR for
linically significant bradycardia was 2.74 (95% CI 2.19 to
.43); in addition, clinically significant hypotension was
ssociated with an adjusted OR of death and stroke of 4.97
95% CI 3.62 to 6.81), whereas clinically significant brady-
ardia was associated with an adjusted OR for death and
troke of 2.13 (95% CI 1.37 to 3.12). Given the association
etween hypotension or bradycardia and morbidity or mor-
ality from the POISE trial, the hemodynamic effects of
erioperative beta blockade must be incorporated and con-
idered in any beta-blocker protocol, with the goal of
voidance of bradycardia and hypotension. The association
f death due to sepsis and beta-blocker use in POISE also
uggests that a thorough search for alternative causes of
achycardia, such as infection, is important. Indeed, patients
ith persistent tachycardia may have alternative causes, such
s sepsis, hypovolemia, pulmonary embolism, and anemia
hat would warrant short-term down titration or even
iscontinuation of beta-blocker therapy. Available evidence
herefore supports an ongoing examination and reexamina-
ion of the indication and contraindications to beta-blocker
herapy throughout the postoperative period.
.2.1.5. SUMMARY (NEW SECTION)
his focused update incorporates important new informa-
ion regarding the risks and benefits of perioperative beta
lockade, as well as expert consensus. In this update, a Class
indication for perioperative beta-blocker use exists for
ontinuation of a beta blocker in patients already taking the
rug. In addition, several Class IIa recommendations exist
or patients with inducible ischemia, coronary artery disease,
r multiple clinical risk factors who are undergoing vascular
i.e., high-risk) surgery and for patients with coronary artery
isease or multiple clinical risk factors who are undergoing
ntermediate-risk surgery. Initiation of therapy, particularly
n lower-risk groups, requires careful consideration of the
isk:benefit ratio for an individual patient. Initiation well
efore a planned procedure with careful titration periopera-
ively to achieve adequate heart rate control while avoiding
rank bradycardia or hypotension is also suggested. In light
f the POISE results, routine administration of periopera-
ive beta blockers, particularly in higher fixed-dose regimens
egun on the day of surgery, cannot be advocated. Ongoing
nd future studies in this area should continue to address
imitations in our evidence base on this subject and provide
urther guidance regarding this important topic.
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Study
Year of
Publication Trial Type
No. of
Patients Patient Population Primary End Point
Analysis: HR,
RR, OR, NNT
95% CI
and/or p Results
angano et al.
(12)
1996 RCT 200 Patients with or at risk for
CAD undergoing
noncardiac surgery
“Overall mortality after
discharge from the
hospital was significantly
lower among the
atenolol-treated patients
than among those who
were given placebo over
the 6 months following
hospital discharge.”
0 versus 8% p0.001 The authors concluded, “The
principal effect was a
reduction in deaths from
cardiac causes during the
first 6 to 8 months.
Combined cardiovascular
outcomes were similarly
reduced among the
atenolol-treated patients;
event-free survival
throughout the 2-year
study period was 68% in
the placebo group and
83% in the atenolol
group; p0.008.”
Over the first year 3% versus 14% p0.005
Over 2 years 10% versus 21% p0.019
allace et al.
(50)
1998 RCT 200 Patients with, or at risk
for, CAD
“The incidence of
myocardial ischemia on
Days 0–2 was
significantly reduced in
the atenolol group
(atenolol, 17 of 99
patients; placebo, 34 of
101 patients).”
p0.008 The authors concluded,
“Perioperative
administration of atenolol
for 1 week to patients at
high risk for CAD
significantly reduces the
incidence of
postoperative myocardial
ischemia. Reductions in
perioperative myocardial
ischemia are associated
with reductions in the risk
for death at 2 years.”
“The incidence of
myocardial ischemia on
Days 0–7 was
significantly reduced in
the atenolol group
(atenolol, 24 of 99
patients; placebo, 39 of
101 patients).”
p0.029
“Patients with episodes of
myocardial ischemia
were more likely to die in
the next 2 years.”
p0.025
oldermans et
al. (5)
1999 Randomized
multicenter
trial
112 Major vascular surgery “The primary study end point
of death due to cardiac
causes or nonfatal MI
occurred in 2 patients in
the bisoprolol group (3.4%)
and 18 in the standard-
care group (34%).”
p0.001 The authors concluded,
“Bisoprolol reduces the
perioperative incidence of
death from cardiac
causes and nonfatal MI in
high-risk patients who are
undergoing major
vascular surgery.”
“Two patients in the
bisoprolol group died of
cardiac causes (3.4%)
compared with 9 in the
standard-care group
(17%).”
p0.02
“Nonfatal MI occurred in 9
patients given standard
care only (17%) and in
none of those given
standard care plus
bisoprolol.”
p0.001
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Analysis: HR,
RR, OR, NNT
95% CI
and/or p Results
augg et al.
(20)
1999 RCT 63 Elderly, noncardiac
surgery patients. Group
I, no atenolol; Group II,
preoperative and
postoperative atenolol;
Group III, intraoperative
atenolol.
“Hormonal markers of the
stress response
(neuropeptide Y,
epinephrine,
norepinephrine, cortisol,
and adrenocorticotropic
hormone) were evaluated
preoperatively and for 72
hours after surgery.”
Perioperative
beta blockade
did not
significantly
alter the
hormonal
stress
response.
The authors concluded,
“Beta-blockade does not
reduce the
neuroendocrine stress
response, suggesting that
this mechanism is not
responsible for the
previously reported
improved cardiovascular
outcome. However, it
confers several
advantages, including
decreased analgesic
requirements, faster
recovery from anesthesia,
and improved
hemodynamic stability.
The release of cardiac
troponin I suggests the
occurrence of
perioperative myocardial
damage in this elderly
population, which
appears to be
independent of the
neuroendocrine stress
response.”
The beta-blocked patients
“received less fentanyl
intraoperatively (27.7%,
p0.0001), experienced
faster early recovery, had
lower pain scores, and
required less analgesia in
the postanesthesia care
unit. Cardiac troponin I
release was detected in 8
of 19, 4 of 20, and 5 of
20 patients in Groups I, II,
and III, respectively
(pnot significant).”
p0.0001
“Three patients in Group I
had cardiac troponin I
levels consistent with MI.”
aby et al. (19) 1999 RCT 26 High-risk vascular surgery
patients
“Ischemia persisted in the
postoperative period in 8
(73%) of 11 placebo
patients but only 5 (33%)
of 15 esmolol patients.”
p0.05 The authors’ data suggest
that “patient-specific,
strict heart rate control
aiming for a predefined
target based on individual
preoperative ischemic
threshold was associated
with a significant
reduction and frequent
elimination of
postoperative myocardial
ischemia among high-risk
patients and provides a
rationale for a larger trial
to examine this strategy’s
effect on cardiac risk.”
rady et al. (22) 2005 Double-blind
RCT
103 Patients without previous
MI who had infrarenal
vascular surgery
“Cardiovascular events
occurred in 15 (34%) and
17 (32%) patients in the
placebo and metoprolol
groups, respectively.”
Unadjusted
RR 0.94
0.53 to 1.66 The authors concluded,
“Myocardial ischemia was
evident in a high
proportion (one-third) of
the patients after surgery.
A pragmatic regimen of
perioperative beta-
blockade with metoprolol
did not seem to reduce
30-day cardiovascular
events, but it did
decrease the time from
surgery to discharge.”
Adjusted
RR 0.87
0.48 to 1.55
JP
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Publication Trial Type
No. of
Patients Patient Population Primary End Point
Analysis: HR,
RR, OR, NNT
95% CI
and/or p Results
“Time from operation to
discharge was reduced
from a median of 12
days (95% CI 9–19 days)
in the placebo group to
10 days (95% CI 8–12
days) in the metoprolol
group.”
Adjusted
HR 1.71
1.09 to 2.66;
p0.02
uul et al. (13) 2006 RCT 921 Patients who have
diabetes 39 years of
age scheduled for
major noncardiac
surgery
“The composite primary
outcome measure was
time to all-cause
mortality, acute MI,
unstable angina, or CHF.”
The authors concluded,
“Perioperative metoprolol
did not significantly affect
mortality and cardiac
morbidity in these
patients with diabetes. CI,
however, were wide, and
the issue needs
reassessment.”
“The primary outcome
occurred in 99 (21%) of
462 patients in the
metoprolol group and 93
(20%) of 459 patients in
the placebo group during
a median follow-up of 18
months (range 6–30
months).”
HR 1.06 0.80 to 1.41
“All-cause mortality was
16% (74 of 462 patients)
in the metoprolol group
and 16% (72 of 459
patients) in the placebo
group.”
HR 1.03 0.74 to 1.42
oldermans et
al. (11)
2006 RCT 1476 Patients undergoing
elective open
abdominal aortic or
infrainguinal arterial
reconstruction
“Patients assigned to no
testing had a similar
incidence of the primary
end point as those
assigned to testing (1.8%
versus 2.3%).”
OR 0.78 0.28 to 2.1;
p0.62
The authors concluded,
“Cardiac testing can
safely be omitted in
intermediate-risk patients,
provided that beta
blockers aiming at tight
[heart rate] control are
prescribed.”
“Regardless of allocated
strategy, patients with a
heart rate65 bpm had
lower risk than the
remaining patients (1.3%
versus 5.2%).”
OR 0.24 0.09 to 0.66;
p0.003
ang et al. (14) 2006 RCT 496 Abdominal aortic surgery
and infrainguinal or
axillofemoral
revascularizations
Primary outcome was
postoperative 30-day
composite incidence of
nonfatal MI, unstable
angina, new CHF, new
atrial or ventricular
dysrhythmia requiring
treatment, or cardiac
death.
The authors concluded,
“Metoprolol was not
effective in reducing the
30-day and 6-month
postoperative cardiac
event rates. Prophylactic
use of perioperative beta
blockers in all vascular
patients is not indicated.”
“Primary outcome events at
30 days occurred in 25
patients (10.2%) versus
30 (12.0%) in the
metoprolol and placebo
groups, respectively.”
RR reduction
15.3%
38.3% to
48.2%;
p0.57
Observed effects at 6
months were not
significantly different.
RR reduction
6.2%
58.4% to
43.8%;
p0.81
Intraoperative bradycardia
requiring treatment was
more frequent in the
metoprolol group (53 of
246 versus 19 of 250
patients).
p0.00001
Intraoperative hypotension
requiring treatment was
more frequent in the
metoprolol group (114 of
246 versus 84 of 250
patients).
p0.0045
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Patients Patient Population Primary End Point
Analysis: HR,
RR, OR, NNT
95% CI
and/or p Results
augg et al.
(21)
2007 Double-blind,
placebo-
controlled,
multicenter
trial
219 Patients undergoing
surgery with spinal
block
“One-year composite
outcome included
cardiovascular mortality,
nonfatal MI, unstable
angina, CHF, and
cerebrovascular insult.”
The authors concluded,
“Perioperative bisoprolol
therapy did not affect
cardiovascular outcome
in these elderly at-risk
patients undergoing
surgery with spinal block.”
“The primary outcome
occurred in 25 patients
(22.7%) in the bisoprolol
group and 24 (22.0%) in
the placebo group during
the 1-year follow-up.”
HR 0.97 0.55 to 1.69;
p0.90
“Carriers of at least 1 Gly
allele of the beta-1-
adrenergic receptor
polymorphism Arg389Gly
showed a higher number
of adverse events than
Arg-homozygous subjects
(32.4% versus 18.7%).”
HR 1.87 1.04 to 3.35;
p0.04
evereaux et al.
(8)
2008 RCT 8331 Patients undergoing
noncardiac surgery
“The primary end point was
a composite of
cardiovascular death,
nonfatal MI, and nonfatal
cardiac arrest. Fewer
patients in the metoprolol
group than in the placebo
group reached the
primary end point (244
[5.8%] patients in the
metoprolol group versus
290 [6.9%] in the
placebo group).”
HR 0.84 0.70 to 0.99;
p0.0399
The authors concluded their
“results highlight the risk
in assuming a
perioperative beta blocker
regimen has benefit
without substantial harm,
and the importance and
need for large
randomized trials in the
perioperative setting.
Patients are unlikely to
accept the risks
associated with
perioperative extended-
release metoprolol.”
“Fewer patients in the
metoprolol group than in
the placebo group had an
MI (176 [4.2%] versus
239 [5.7%] patients).”
HR 0.73 0.60 to 0.89;
p0.0017
“More deaths occurred in
the metoprolol group
than in the placebo group
(129 [3.1%] versus 97
[2.3%] patients).”
HR 1.33 1.03 to 1.74;
p0.0317
“More patients in the
metoprolol group than in
the placebo group had a
stroke (41 [1.0%] versus
19 [0.5%] patients).”
HR 2.17 1.26 to 3.74;
p0.0053
unkelgrun et
al. (6)
2009 RCT 1066 Intermediate-risk patients
undergoing
noncardiovascular
surgery
The primary end point was
the composite of
perioperative cardiac
death and nonfatal MI.
The authors concluded, “In
intermediate-risk surgical
patients, bisoprolol was
associated with a
significant reduction of
30-day cardiac
complications, while
fluvastatin showed a
trend for improved
outcome.”
“Patients randomized to
bisoprolol (n533) had a
lower incidence of the
primary end point than
those randomized to
bisoprolol-control therapy
(2.1% versus 6.0%
events).”
HR 0.34 0.17 to 0.67;
p0.002
PP
Y
2124 Fleischmann et al. JACC Vol. 54, No. 22, 2009
Focused Update on Perioperative Beta Blockade November 24, 2009:2102–28Study
Year of
Publication Trial Type
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Patients Patient Population Primary End Point
Analysis: HR,
RR, OR, NNT
95% CI
and/or p Results
“The beneficial effects of
bisoprolol were not
modified by fluvastatin.
Patients randomized to
fluvastatin experienced a
lower incidence of the
primary efficacy end
point than those
randomized to
fluvastatin-control
therapy (3.2% versus
4.9% events).”
HR 0.65 0.35 to 1.10;
p0.17
Nonrandomized Studies
asternack et
al. (16)
1987 83 Patients scheduled for
abdominal aortic
aneurysm surgery
Group 1 was treated with
oral metoprolol
immediately before
surgery and with
intravenous metoprolol
during the postoperative
period. Group 2, who did
not receive metoprolol,
served as a control.
The authors concluded that
their “data demonstrate
that beta blockade with
metoprolol is effective in
controlling systolic blood
pressure and heart rate
both intraoperatively and
postoperatively in
patients undergoing
repair of AAA and can
significantly reduce the
incidence of perioperative
MI and arrhythmias.”
“In Group 1, only 1 patient
(3%) had an acute MI. In
contrast, 9 Group 2
patients (18%) had
perioperative MI.
p0.05
Only 4 Group 1 patients
(12.5%) developed
significant cardiac
arrhythmias as opposed
to 29 Group 2 patients
(56.9%).”
p0.001
asternack et
al. (17)
1989 Clinical trial 48 Peripheral vascular
surgery patients
“Patients treated with oral
metoprolol had
significantly less
intraoperative silent
ischemia with respect to
relative duration and
frequency of episodes, a
significantly lower
intraoperative heart rate,
and less intraoperative
silent myocardial
ischemia in terms of total
absolute duration.”
The authors concluded,
“These results suggest
that beta-adrenergic
activation may play a
major role in the
pathogenesis of silent
myocardial ischemia
during peripheral vascular
surgery.”
eager et al.
(18)
1995 Case-control
study
159 Vascular surgery “Beta blockers were used
less frequently in patients
with perioperative MI
than in control patients
without perioperative MI
(30% versus 50%).”
p0.01 The authors concluded,
“Beta blockade is
associated with a
decreased incidence of
perioperative MI in
patients undergoing
vascular surgery.
Prophylactic perioperative
use of beta-blockers may
decrease perioperative MI
in patients requiring
major vascular surgery.”
“Overall, beta blockade was
associated with a 50%
reduction in perioperative
MI.”
p0.03
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Patients Patient Population Primary End Point
Analysis: HR,
RR, OR, NNT
95% CI
and/or p Results
oersma et al.
(4)
2001 Cohort study 1351 Of patients undergoing
major vascular surgery,
611 patients (45%)
had a Lee risk index of
1; 509 (38%) had an
index of 2; and 231
(17%) had an index of
3 points (all patients
underwent high-risk
surgery and thus had a
risk index1 point).
Cardiac death or nonfatal
MI within 30 days after
surgery was the main
outcome measure,
compared by clinical
characteristics, DSE
results, and beta blocker
use.
The authors concluded the
“additional predictive
value of DSE is limited in
clinically low-risk patients
receiving beta blockers. In
clinical practice, DSE may
be avoided in a large
number of patients who
can proceed safely for
surgery without delay. In
clinically intermediate-
and high-risk patients
receiving beta blockers,
DSE may help identify
those in whom surgery
can still be performed
and those in whom
cardiac revascularization
should be considered.”
Among the 83% of patients
with 3 clinical risk
factors, patients receiving
beta blockers had a lower
risk of cardiac
complications (0.8% [2 of
263]) than those not
receiving beta blockers
(2.3% [20 of 855]), and
DSE had minimal
additional prognostic
value. In patients with
3 risk factors (17%),
DSE provided additional
prognostic information;
patients without stress-
induced ischemia had a
much lower risk of events
than those with stress-
induced ischemia
(among those receiving
beta blockers, 2.0% [1 of
50] versus 10.6% [5 of
47]). Patients with
limited stress-induced
ischemia (1-4 segments)
experienced fewer
cardiac events (2.8% [1
of 36]) than those with
more extensive ischemia
(5 segments, 36% [4 of
11]).
“Patients who did not
undergo DSE (i.e.,
patients without clinical
cardiac risk factors) and
those without NWMAs
during DSE had a
significantly lower cardiac
death or MI rate than
patients with NWMAs
during DSE (0.4% and
1.6% versus 13.5%,
respectively).”
p0.001
“In the 222 patients with
NWMAs, 67% received
beta blockers, with 4.7%
having a perioperative
cardiac event versus
31.5% of those not
receiving beta blockers.”
Mantel-Haenszel
test 0.1
0.1 to 0.3
222 Univariable relation
between DSE results and
perioperative cardiac
death or MI: NWMA (DSE
summary).
OR 39.5 5.3 to 292;
p0.001
SL
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Analysis: HR,
RR, OR, NNT
95% CI
and/or p Results
“Multivariable model: After
correction for differences
in clinical characteristics,
patients receiving beta
blockers were still at
significantly lower risk for
the composite end point
than those who were not.”
Adjusted OR 0.3 0.1 to 0.7
“DSE results (especially the
presence or absence of
NWMAs) were the most
important determinants
of perioperative cardiac
outcome. In connection
with both clinical data
and DSE results, beta-
blocker therapy was
again associated with a
significantly reduced risk
of the composite end
point. The protective
effect of beta-blocker
therapy was observed in
long-term users and in
patients who received
bisoprolol as part of the
DECREASE study (OR 0.1,
95% CI 0.0 to 0.4).”
OR 0.1 0.0 to 0.3
“The incidence of the
composite end point in
patients with a Lee index
of 1, 2, or 3 points was
1.3%, 3.1%, and 9.1%,
respectively.”
p0.001
hammash et
al. (47)
2001 140 Major vascular surgical
procedures
“Mortality in the 8 patients
who had beta blockers
discontinued
postoperatively (50%)
was significantly greater
than mortality (1.5%) in
132 patients who
continued taking beta
blockers.”
OR 65.0 p0.001 The authors concluded,
“Discontinuing beta
blockers immediately
after vascular surgery
may increase the risk of
postoperative
cardiovascular morbidity
and mortality.”
“Beta-blocker
discontinuation also was
associated with increased
cardiovascular mortality
(0% versus 29%).”
p0.005
“Beta-blocker
discontinuation also was
associated with increased
postoperative MI.”
OR 17.7 p0.003
indenauer et
al. (7)
2005 Retrospective
cohort study
663 635 Patients18 years of
age who underwent
major noncardiac
surgery
“Among the 580 665
patients with an RCRI
score of 0 or 1, treatment
was associated with no
benefit and possible
harm.”
Adjusted
OR 1.09
1.01 to 1.19 The authors concluded,
“Perioperative beta-
blocker therapy is
associated with a reduced
risk of in-hospital death
among high-risk, but not
low-risk, patients
undergoing major
noncardiac surgery.
Patient safety may be
enhanced by increasing
the use of beta-blockers
in high-risk patients.”
RCRI score 2 Adjusted
OR 0.88
0.80 to 0.98
RCRI score 3 Adjusted
OR 0.71
0.63 to 0.80
RCRI score4 Adjusted
OR 0.58
0.50 to 0.67
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and/or p Results
edelmeier et
al. (30)
2005 Retrospective
cohort study
37 151 Patients 65 years of
age who were admitted
for elective surgery,
without symptomatic
coronary disease
1038 patients experienced
an MI or died, at a rate
that was significantly
lower for patients
receiving atenolol than
for those receiving
metoprolol (2.5% versus
3.2%).
p0.001 The authors concluded,
“Patients receiving
metoprolol do not have as
low a perioperative
cardiac risk as patients
receiving atenolol, in
accord with possible
acute withdrawal after
missed doses.”
eringa et al.
(40)
2006 Observational
cohort study
272 Vascular surgery “In multivariate analysis,
higher beta-blocker doses
(per 10% increase) were
significantly associated
with a lower incidence of
myocardial ischemia.”
HR 0.62 0.51 to 0.75 The authors concluded,
“This study showed that
higher doses of beta
blockers and tight heart
rate control are
associated with reduced
perioperative myocardial
ischemia and troponin T
release and improved
long-term outcome in
vascular surgery
patients.”
Troponin T release HR 0.63 0.49 to 0.80
Long-term mortality HR 0.86 0.76 to 0.97
“Higher heart rates during
electrocardiographic
monitoring (per 10-bpm
increase) were
significantly associated
with an increased
incidence of myocardial
ischemia.”
HR 2.49 1.79 to 3.48
Troponin T release HR 1.53 1.16 to 2.03
Long-term mortality HR 1.42 1.14 to 1.76
oeks et al.
(48)
2006 Prospective
survey
711 Peripheral vascular
surgery patients
“After adjustment for
potential confounders
and the propensity of its
use, continuous beta-
blocker use remained
significantly associated
with a lower 1-year
mortality compared with
nonusers.”
HR 0.4 0.2 to 0.7 The authors concluded that
this “study demonstrated
an under-use of beta
blockers in vascular
surgery patients, even in
high-risk patients.
Perioperative beta-blocker
use was independently
associated with a lower
risk of 1-year mortality
compared to non-use,
while perioperative
withdrawal of beta-
blocker therapy was
associated with a higher
1-year mortality.”
“In contrast, beta-blocker
withdrawal was
associated with an
increased risk of 1-year
mortality compared with
nonusers.”
HR 2.7 1.2 to 5.9
aafarani et al.
(32)
2008 Retrospective
cohort study
646 All patients who
underwent various
noncardiac surgical
procedures
“Patients at all levels of
cardiac risk who received
beta blockers had lower
preoperative and
intraoperative heart
rates.”
The authors concluded,
“Among patients at all
levels of cardiac risk
undergoing noncardiac
surgery, administration of
beta blockers should
achieve adequate heart
rate control and should
be carefully monitored in
patients who are not at
high cardiac risk.”
The beta-blocker group had
higher rates of 30-day MI
(2.94% versus 0.74%)
than the control group.
p0.03
The beta-blocker group had
higher 30-day mortality
(2.52% versus 0.25%)
than the control group.
p0.007
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Patients in the beta-blocker
group who died
perioperatively had
significantly higher
preoperative heart rate
(86 versus 70 bpm).
p0.03
atyal et al.
(33)
2008 Retrospective 960 Vascular surgery
(primarily infrainguinal)
“Adverse outcome was
defined as MI, new-onset
CHF, significant
arrhythmias, renal failure,
or death. The incidence
of adverse outcomes was
lower when beta blockers
were administered in
men (12.6% versus
18.9%).”
p0.04 The authors concluded,
“Women did not benefit
from perioperative beta-
blockade. Women at high
risk appeared to have a
worse outcome because
of a higher incidence of
CHF.”
“The incidence of adverse
outcomes was not lower
in women (17.8% versus
13.7%).”
p0.37
“Among beta-blocker–naïve
subjects, men had
significant reductions in
MI and renal failure,
whereas women did not
have a reduction in the
incidence of any
outcome.”
“After risk stratification, the
high-risk women who
received beta blockade
had a statistically worse
outcome (36.8% versus
5.9%) because of an
increased incidence of
CHF.”
p0.02
AA indicates abdominal aortic aneurysm; bpm, beats per minute; CAD, coronary artery disease; CHF, congestive heart failure; CI, confidence interval; DSE, dobutamine stress echocardiography; HR,
azard ratio; MI, myocardial infarction; n, number; NNT, number needed to treat; NWMA, new wall-motion abnormality; OR, odds ratio; RCRI, Revised Cardiac Risk Index; RCT, randomized controlled
rial; and RR, relative risk.
